Perrigo Co. plc, with a diversified revenue stream, sells infant formulas for the store brand market, generic extended topical prescription (Rx) products and specialty pharmaceutical drugs. It's focusing on self-care products as part of its transformation into a self-care company from a healthcare company. The company divested its Rx segment to Altaris Capital Partners. The company completed its transformation to a consumer self-care company by reconfiguring the portfolio through the divestiture of RX business. Currently, the company has 2 reporting segments. Consumer Self Care Americas (CSCA): The segment comprises the U.S., Mexico and Canada CHC business, including OTC, contract manufacturing, infant formula and animal health categories. Consumer Self Care International?(CSCI): The segment comprises the branded consumer healthcare (BCH) segment mainly in Europe and the company's consumer-focused businesses in the UK and Australia. This segment includes UK liquids licensed products business.
Revenue (Most Recent Fiscal Year) | $4.37B |
Net Income (Most Recent Fiscal Year) | $-171.80M |
PE Ratio (Current Year Earnings Estimate) | 7.91 |
PE Ratio (Trailing 12 Months) | 8.13 |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 0.75 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.73 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 4.69 |
Pre-Tax Margin (Trailing 12 Months) | 2.39% |
Net Margin (Trailing 12 Months) | -1.86% |
Return on Equity (Trailing 12 Months) | 9.09% |
Return on Assets (Trailing 12 Months) | 3.96% |
Current Ratio (Most Recent Fiscal Quarter) | 2.32 |
Quick Ratio (Most Recent Fiscal Quarter) | 1.24 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.81 |
Inventory Turnover (Trailing 12 Months) | 2.43 |
Book Value per Share (Most Recent Fiscal Quarter) | $32.51 |
Earnings per Share (Most Recent Fiscal Quarter) | $0.57 |
Earnings per Share (Most Recent Fiscal Year) | $2.57 |
Diluted Earnings per Share (Trailing 12 Months) | $-0.58 |
Exchange | NYSE |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Common Shares Outstanding | 137.58M |
Free Float | 136.62M |
Market Capitalization | $3.26B |
Average Volume (Last 20 Days) | 1.77M |
Beta (Past 60 Months) | 0.47 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 0.70% |
Percentage Held By Institutions (Latest 13F Reports) | 95.91% |
Annual Dividend (Based on Last Quarter) | $1.16 |
Dividend Yield (Based on Last Quarter) | 4.90% |